Clinical trials of combining PD-1/PD-L1/CTLA-4 blockades with MAPK inhibitors, EGFR inhibitors or BRAF and MEK inhibitor are underway in BRAF-mutant and wide-type melanoma.624–628 Recent studies of combined VEGF inhibitor, apatinib, and an investigational humanized IgG4 monoclonal antibody against PD-1, camrelizumab demonstrates an ORR of 22.2% in advanced untreated acral melanoma patients,629 and longer follow-up time is needed to confirm the efficacy of the combinatorial regimen. Here, CTLA4 is linked to melanoma.